ISRCTN ISRCTN84214355
DOI https://doi.org/10.1186/ISRCTN84214355
ClinicalTrials.gov (NCT) NCT00003893
Protocol serial number BR3015
Sponsor University Hospitals Birmingham NHS Foundation Trust (UK)
Funder Cancer Research UK (UK)
Submission date
01/07/2001
Registration date
01/07/2001
Last edited
25/01/2019
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Sarah Bowden
Scientific

CRUK Clinical Trials Unit
Institute for Cancer Studies
The University of Birmingham
Edgbaston
Birmingham
B15 2TT
United Kingdom

Phone +44 (0)121 414 4371
Email BTT@bham.ac.uk

Study information

Primary study designInterventional
Study designRandomised controlled trial
Secondary study designRandomised controlled trial
Study type Participant information sheet
Scientific titleSequencing of Chemotherapy and Radiotherapy in Adjuvant Breast cancer
Study acronymSECRAB
Study objectivesTo answer reliably two questions in the timing of delivery of chemotherapy and radiotherapy in the adjuvant treatment of early breast cancer:
1. Can local control be improved by synchronous delivery of adjuvant chemotherapy and radiotherapy thereby not delaying the administration of either modality?
2. Can synchronous chemotherapy and radiotherapy be given safely without significant enhancement of acute or late toxicity, without compromising on dose intensity of either modality and without adversely affecting quality of life or cosmesis?
Ethics approval(s)West Midlands Research Ethics Committee, 09/04/1998, MREC/98/7/16
Health condition(s) or problem(s) studiedBreast cancer
InterventionTwo arms:
Arm 1 - Synchronous treatment (Chemotherapy - Radiotherapy - Chemotherapy)
Arm 2 - Sequential treatment (Chemotherapy - Radiotherapy)
Intervention typeOther
Primary outcome measure(s)

Local tumour recurrence rates at 5 and 10 years

Key secondary outcome measure(s)

1. Distant and overall recurrence rates
2. Survival at 5, 10 and 15 years
3. Acute toxicity causing significant treatment delay or dose reduction
4. Other late effects of treatment

Completion date25/03/2004

Eligibility

Participant type(s)Patient
Age groupAdult
SexFemale
Target sample size at registration2298
Key inclusion criteria1. Histological diagnosis of invasive breast carcinoma (unilateral if participating in the Cosmesis Study)
2. Wide local excision or mastectomy with macroscopic complete excision of clinically early stage disease and no evidence of metastases
3. There is a clear indication for both adjuvant chemotherapy and radiotherapy, or the patient has been randomised to these treatments in another study
4. The intended schedules can be given synchronously and the patient is considered suitable to receive either treatment sequence
5. Medically fit enough to complete chemotherapy and radiotherapy, with adequate cardiac, renal, hepatic and bone marrow function
6. The patient has given written informed consent
7. No prior chemotherapy (other than hormone manipulation)
8. No prior malignancy (except skin basal/squamous cell or in situ carcinoma)
9. Not currently pregnant or lactating, no intention of pregnancy during treatment
10. No other medical or social contra-indication to entry and follow-up
Key exclusion criteriaN/A
Date of first enrolment02/07/1998
Date of final enrolment25/03/2004

Locations

Countries of recruitment

  • United Kingdom
  • England

Study participating centre

CRUK Clinical Trials Unit
Birmingham
B15 2TT
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summary
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/04/2006 25/01/2019 Yes No
Participant information sheet Participant information sheet 11/11/2025 11/11/2025 No Yes
Plain English results No Yes

Editorial Notes

25/01/2019: Publication reference added
17/10/2018: Cancer Research UK lay results summary link added to Results (plain English)
09/06/2017: No publications found in PubMed, verifying study status with principal investigator.